SCNI: Scinai Immunotherapeutics Ltd Company Value to Net Income

BiondVax Pharmaceuticals - graphic logo of issuer SCNI

Scinai Immunotherapeutics (SCNI) relies on a cohesive staff of immunologists, strategically recruiting clinical trial specialists. The business's innovative foundation consists of a nanobody platform for the rapid creation of defenses against pandemic threats. This price action chart featuring the -0.20 metric demonstrates the company's market context. The Israeli developer employs a flexible R&D approach, allowing for the accelerated adaptation of formulas to new viruses while maintaining a stable laboratory base.

Scinai Immunotherapeutics Ltd. (SCNI) Price to Earnings Ratio: for the period 05/18/2024 - 11/17/2026

Analytical breakdowns for BiondVax Pharmaceuticals (SCNI)

- price and consensus price forecast:
Comprehensive company analysis:Scinai Immunotherapeutics Ltd. SCNI
Signature product of Scinai

It is critically important for Scinai Immunotherapeutics (SCNI) investors to compare the business's market value with its actual ability to generate profit. This metric measures the ratio of market capitalization to net income, revealing whether the asset is overvalued or undervalued. By analyzing the company's historical average P/E, one can identify points of extreme risk or advantageous entry. For this Israeli business, this indicator reflects capital resilience against regional instability. Global partnerships of Scinai Immunotherapeutics smooth out chart volatility, confirming the company's fundamental value.

Key competitors

P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Price to Earnings Ratio|Grifols Biemat (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotechnologies|Price to Earnings Ratio CLDX|P/E Multiple auriniapharma.com|Price to Earnings Ratio BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Earnings Multiple|P/E Multiple DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Market Cap to Earnings|AbCellera Biologics - P/E Multiple|tourmalinebio.com - Market Price to Net Income Ratio|Precigen (PGEN) - Price to Earnings Ratio|Pharming Group - Company Value to Net Income|Price to Earnings Ratio Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Price to Net Income Ratio|P/E Multiple ZBIO|P/E Multiple immunome.com (IMNM)|P/E Multiple GOSS (gossamerbio.com)|Business Payback Period KalVista Pharma (KALV)|SEPN - Price to Earnings Ratio|Business Payback Period Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Price to Earnings Ratio|Market Cap to Net Income RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Price to Net Income Ratio|Price to Earnings Ratio engene.com (ENGN)|RAPT (RAPT Therapeutics, Inc.) - Company Value to Net Income|Aerovate Therapeutics - Price to Earnings Ratio|Company Value to Net Income ACRS|Kyverna Therapeutics, Inc - P/E Multiple|Market Cap to Net Income TLSA|CABA: P/E Multiple|Price to Earnings Ratio Ventyx Bio|Price to Earnings Ratio Theratechnologies, Inc.|Market Cap to Earnings Avalo Therapeutics AVTX|P/E Multiple ELDN|AGEN (Agenus, Inc.) - Company Value to Net Income|Price to Earnings Ratio Climb Bio, Inc. CLYM|Zura Bio Limited (ZURA) - Market Cap to Earnings|ATYR: Price to Earnings Ratio|adagene.com (ADAG) - Price to Earnings Ratio|Ikena Oncology (IMA) - Price to Earnings Ratio|Price to Earnings Ratio Shattuck Labs, Inc.|Price to Earnings Ratio equilliumbio.com|Price to Earnings Ratio connectbiopharm.com (CNTB)|P/E Multiple IMUX|Business Payback Period Atara Bio|Price to Earnings Ratio InflaRx N.V. IFRX|X4 Pharmaceuticals - Price to Earnings Ratio|ACET: Price to Earnings Ratio|Company Value to Net Income CELU (celularity.com)|INMB: P/E Multiple|BRNS: Market Price to Net Income Ratio|KZR (Kezar Life Sciences, Inc.) - P/E Multiple|SAB Biotherapeutics Inc. (SABS) - Business Payback Period|P/E Multiple AKTX|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd)|Price to Earnings Ratio Q32 Bio Inc. QTTB|GOVX - Price to Earnings Ratio|EDSA - Price to Earnings Ratio|Market Cap to Earnings iBio|CARM: P/E Multiple|Market Cap to Net Income XTLB (XTL Biopharmaceuticals, Ltd.)|Price to Earnings Ratio boltbio.com|P/E Multiple HCW Biologics|P/E Multiple APVO|AIM - Market Cap to Earnings|P/E Multiple ADTX (Aditxt Inc.)|Business Payback Period GRI Bio, Inc. (GRI)|XRTX - Price to Earnings Ratio|reshapelifesciences.com (HIND) - Price to Earnings Ratio|REVB: P/E Multiple|Indaptus Therapeutics, Inc. - Company Value to Net Income|CALI (CalciMedica Inc) - P/E Multiple|affimed.com - Market Cap to Net Income|Price to Earnings Ratio allakos.com (ALLK)|P/E Multiple HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Price to Earnings Ratio|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple